Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
- PMID: 3045807
- PMCID: PMC281868
- DOI: 10.1073/pnas.85.16.5879
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
Abstract
A biosynthetic antibody binding site, which incorporated the variable domains of anti-digoxin monoclonal antibody 26-10 in a single polypeptide chain (Mr = 26,354), was produced in Escherichia coli by protein engineering. This variable region fragment (Fv) analogue comprised the 26-10 heavy- and light-chain variable regions (VH and VL) connected by a 15-amino acid linker to form a single-chain Fv (sFv). The sFv was designed as a prolyl-VH-(linker)-VL sequence of 248 amino acids. A 744-base-pair DNA sequence corresponding to this sFv protein was derived by using an E. coli codon preference, and the sFv gene was assembled starting from synthetic oligonucleotides. The sFv polypeptide was expressed as a fusion protein in E. coli, using a leader derived from the trp LE sequence. The sFv protein was obtained by acid cleavage of the unique Asp-Pro peptide bond engineered at the junction of leader and sFv in the fusion protein [(leader)-Asp-Pro-VH-(linker)-VL]. After isolation and renaturation, folded sFv displayed specificity for digoxin and related cardiac glycosides similar to that of natural 26-10 Fab fragments. Binding between affinity-purified sFv and digoxin exhibited an association constant [Ka = (3.2 +/- 0.9) x 10(7) M-1] that was about a factor of 6 smaller than that found for 26-10 Fab fragments [Ka = (1.9 +/- 0.2) x 10(8) M-1] under the same buffer conditions, consisting of 0.01 M sodium acetate, pH 5.5/0.25 M urea.
Similar articles
-
Medical applications of single-chain antibodies.Int Rev Immunol. 1993;10(2-3):195-217. doi: 10.3109/08830189309061696. Int Rev Immunol. 1993. PMID: 8360586 Review.
-
A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv.Biochemistry. 1990 Sep 4;29(35):8024-30. doi: 10.1021/bi00487a005. Biochemistry. 1990. PMID: 2261460
-
Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.Tissue Antigens. 1996 Jan;47(1):1-20. doi: 10.1111/j.1399-0039.1996.tb02509.x. Tissue Antigens. 1996. PMID: 8929708
-
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.Protein Eng. 1995 Mar;8(3):301-14. doi: 10.1093/protein/8.3.301. Protein Eng. 1995. PMID: 7479692
-
Biosynthetic antibody binding sites: development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315.J Protein Chem. 1991 Dec;10(6):669-83. doi: 10.1007/BF01025718. J Protein Chem. 1991. PMID: 1815591 Review.
Cited by
-
A functionally neutral single chain antibody to measure beta-1 integrin uptake and recycling.Traffic. 2020 Sep;21(9):590-602. doi: 10.1111/tra.12754. Epub 2020 Jul 21. Traffic. 2020. PMID: 32613646 Free PMC article.
-
Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.Protein Expr Purif. 2021 Jan;177:105766. doi: 10.1016/j.pep.2020.105766. Epub 2020 Sep 25. Protein Expr Purif. 2021. PMID: 32987122 Free PMC article.
-
Targeted multiplex imaging mass spectrometry with single chain fragment variable (scfv) recombinant antibodies.J Am Soc Mass Spectrom. 2012 Oct;23(10):1689-96. doi: 10.1007/s13361-012-0423-x. Epub 2012 Aug 7. J Am Soc Mass Spectrom. 2012. PMID: 22869296 Free PMC article.
-
CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care.Asia Pac J Oncol Nurs. 2024 Aug 23;11(10):100579. doi: 10.1016/j.apjon.2024.100579. eCollection 2024 Oct. Asia Pac J Oncol Nurs. 2024. PMID: 39315365 Free PMC article. Review.
-
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability.MAbs. 2024 Jan-Dec;16(1):2394230. doi: 10.1080/19420862.2024.2394230. Epub 2024 Aug 27. MAbs. 2024. PMID: 39192463 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources